Retina Specialty CRO Climbs Nearly 300 Spots to No. 434, Reinforcing Its Leadership
as the Premier Partner for Retina Companies
NASHVILLE, Tenn., Aug. 13, 2025 /PRNewswire/ — InFocus Clinical Research today announced it has been ranked No. 434 on the 2025 Inc. 5000 list, a significant leap from its position at No. 724 in 2024. The Inc. 5000 recognizes the fastest-growing privately held companies in the United States.
In addition to its national ranking, InFocus earned top recognition in several categories:
“This recognition reflects not only rapid growth but our unwavering commitment to quality partnerships and advancing retina research,” said Brad Doerschuk, CEO of InFocus. “We’ve built a model that is therapeutically focused, site-aligned, and intentionally different — and it’s making a measurable impact.”
InFocus is the only global CRO purpose-built for retina. Founded by retina stakeholders, the company leverages deep therapeutic expertise, long-standing relationships with top-performing sites, and its proprietary Real-Time Intelligence (RTI) database — encompassing more than 400 global retina clinics — to deliver smarter site selection, stronger enrollment, and agile trial execution.
“We’re proud of the progress we’ve made, but we’re even more energized by what’s ahead,” Doerschuk added. “As new therapies emerge and trial complexity increases, we’re doubling down on our mission to be the most trusted, responsive, and retina-focused CRO in the world.”
The full Inc. 5000 list is available at www.inc.com/inc5000.
About InFocus Clinical Research
InFocus Clinical Research is a global, full-service contract research organization (CRO) focused exclusively on retina diseases. Founded in 2015 by retina experts, the company combines therapeutic depth, operational agility, and a specialized site network to deliver high-performing clinical trials. With dedicated scientific leadership, InFocus partners with sponsors to accelerate innovation in retinal disease.
SOURCE InFocus Clinical Research
Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…
Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…
Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…
Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…
Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists…
Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…